HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine: What about safety in France?

被引：0
|
作者：
Ativon, F. [1 ]
Lebeller, C. [2 ]
Schiestel, T. [3 ]
Grandvuillemin, A. [4 ]
Davani, S. [1 ]
Valnet-Rabier, M. B. [1 ]
机构：
[1] Ctr Reg Pharmacovigilance Franche Comte, Besancon, France
[2] Ctr Reg Pharmacovigilance Paris, HEGP, Paris, France
[3] Ctr Reg Pharmacovigilance Paris Fernand Widal, Paris, France
[4] Ctr Reg Pharmacovigilance Bourgogne, Dijon, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2021年 / 35卷
关键词：
HIV PrEP; TDF/emtricitabine; safety;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PS-117
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [41] Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo, Alexa B.
    Westmoreland, Drew A.
    Carneiro, Pedro B.
    Johnson, Jeremiah
    Grov, Christian
    AIDS PATIENT CARE AND STDS, 2021, 35 (08) : 327 - 334
  • [42] Urine tenofovir and emtricitabine concentrations provide biomarker for exposure to HIV preexposure prophylaxis
    Haaland, Richard E.
    Martin, Amy
    Holder, Angela
    Fountain, Jeffrey J.
    Hall, LaShonda
    Pescatore, Nicole A.
    Heeke, Sheila
    Kelley, Colleen F.
    AIDS, 2017, 31 (11) : 1647 - 1650
  • [43] Longer term safety of emtricitabine/tenofovir alafenamide (F/TAF) and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): DISCOVER trial week 96 results
    Ogbuagu, O.
    Podzamczer, D.
    Salazar, L.
    Henry, K.
    Asmuth, D.
    Wohl, D.
    Gilson, R.
    Shao, Y.
    Ebrahimi, R.
    Carter, C.
    Das, M.
    McCallister, S.
    Brunetta, J.
    Kronborg, G.
    Reeves, I.
    Spinner, C.
    HIV MEDICINE, 2020, 21 : 12 - 12
  • [44] Concentrations of Tenofovir and Emtricitabine in Saliva: Implications for Preexposure Prophylaxis of Oral HIV Acquisition
    de Lastours, Victoire
    Fonsart, Julien
    Burlacu, Ruxandra
    Gourmel, Bernard
    Molina, Jean-Michel
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (10) : 4905 - 4907
  • [45] Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
    Kabbaral, Wissam K.
    Ramadan, Wijdan H.
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2015, 8 (05) : 409 - 417
  • [46] Emtricitabine/Tenofovir Disoproxil Fumarate In Combination with a Protease Inhibitor in HIV-1 Infection
    Perry, Caroline M.
    DRUGS, 2009, 69 (07) : 843 - 857
  • [47] Emtricitabine/tenofovir disoproxil fumarate/etravirineDevelopment of drug resistance in HIV infection: case report
    Reactions Weekly, 2017, 1669 (1) : 119 - 119
  • [48] Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection
    Del Amo, Julia
    Polo, Rosa
    Moreno, Santiago
    Martinez, Esteban
    Cabello, Alfonso
    Iribarren, Jose Antonio
    Curran, Adria
    Macias, Juan
    Montero, Marta
    Duenas, Carlos
    Marino, Ana I.
    de la Camara, Santiago Perez
    Diaz, Asuncion
    Arribas, Jose Ramon
    Jarrin, Inma
    Hernan, Miguel A.
    AIDS, 2022, 36 (15) : 2171 - 2179
  • [49] Changes in Glomerular Kidney Function Among HIV-1-Uninfected Men and Women Receiving Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis A Randomized Clinical Trial
    Mugwanya, Kenneth K.
    Wyatt, Christina
    Celum, Connie
    Donnell, Deborah
    Mugo, Nelly R.
    Tappero, Jordan
    Kiarie, James
    Ronald, Allan
    Baeten, Jared M.
    JAMA INTERNAL MEDICINE, 2015, 175 (02) : 246 - 254
  • [50] Efficacy and Safety of Dolutegravir With Emtricitabine and Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate, and Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate HIV Antiretroviral Therapy Regimens Started in Pregnancy oIMPAACT 2010/VESTEDTHORN: A Multicentre, Open-label, Randomised, Controlled, Phase 3 Trial
    Aquino, Marcella
    PEDIATRICS, 2021, 148 : S70 - S70
12345